Premium
FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL
Author(s) -
Gressin R.,
Daguindau N.,
Tempescul A.,
Moreau A.,
Carras S.,
Cartron G.,
Schmitt A.,
Houot R.,
Dartigeas C.,
Pig J.,
Corm S.,
Bannos A.,
Mounier C.,
Dupuis J.,
Macro M.,
Fleury J.,
Jardin F.,
Karlin L.,
Damaj G.,
Feugier P.,
Fornecker L.,
Chabrot C.,
Ysebaert I.,
Callanan M.,
Le Gouill S.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_131
Subject(s) - bendamustine , medicine , rituximab , regimen , bortezomib , mantle cell lymphoma , gastroenterology , cytarabine , neutropenia , surgery , oncology , multiple myeloma , lymphoma , chemotherapy